ISO 10993-1: How Device Materials Are Screened Before Sale
Quick summary: ISO 10993-1 is the framework behind every biocompatibility statement you read on a clinic supply specification sheet. It organises devices by the nature and duration of body contact, then asks what evidence already exists before any laboratory testing is ordered. Understanding it lets a buyer ask sharper questions about gloves, tape, gowns and dressings without needing a laboratory background.
A purchasing manager comparing two quotes for examination gloves will see lines that look like marketing and lines that look like engineering. Biocompatibility falls into a third category: it is a regulatory expectation dressed in scientific language, and it decides whether a product can be sold in the first place.
The framework that organises this work is ISO 10993-1. It is the part of the ISO 10993 series that describes evaluation and testing within a risk management process — planning tool more than test method. This guide explains what it covers and how to read the claims that flow from it.
Why Does a Clinic Buyer Meet ISO 10993-1?
Medical devices sold in Canada fall under the Medical Devices Regulations, SOR/98-282, which sit under the Food and Drugs Act. A device must be safe and effective for its intended use, and for anything that touches a patient the question of material safety is part of that file. Manufacturers address it using a recognised biological evaluation framework; ISO 10993-1 is the one most often referenced internationally.
Clinics rarely read the technical file. What they see is a specification sheet, a certificate, or a line in a supplier's catalogue. Knowing what sits behind those lines is how a buyer separates a documented claim from a slogan — the same discipline that applies to AQL sampling plans and to allergy and irritation distinctions on gloves.
What Is ISO 10993-1 Actually For?
ISO 10993-1:2018 is titled Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process. Two phrases carry the weight. "Biological evaluation" means assessing how a material interacts with the body. "Within a risk management process" means the evaluation is planned and documented like any other risk activity, alongside design, manufacturing and post-market information.
The practical consequence is that the standard does not hand you a fixed test list. It asks for a structured judgement: what is this device, where does it touch the body, for how long, and what do we already know? Only after those questions are answered does a testing plan get written.
That structure is why two products with similar chemistry can carry different evidence packages. A 4 mil nitrile examination glove used for a single patient contact and a hypoallergenic paper tape left in place for days are both surface contact devices, but their exposure profiles are not the same.
What Are the Three Questions the Framework Asks?
The categorisation step comes first, and it is deliberately simple.
- What kind of contact is it? Surface contact with intact skin or mucosa, external communicating contact through a route such as a device that touches circulating blood or tissue, or an implant. Most consumable clinic supply sits in the surface category.
- How long is the contact? Exposure is grouped by duration, with a limited category, a prolonged category and a long-term category, using boundaries that the standard defines.
- What evidence already exists? Material composition, prior use of the same material in a comparable device, published data and clinical history all count before new testing is commissioned.
| Contact picture | Duration band | Typical clinic supply examples |
|---|---|---|
| Intact skin, brief contact | Limited | Examination gloves for a single procedure; a dressing change |
| Intact skin, repeated or longer contact | Prolonged | Tape and adhesive products left in place; gloves worn through a clinic session |
| Mucosa or compromised skin | Limited to prolonged | Products used in wound or oral care pathways |
| Indirect contact with circulating blood | Limited to prolonged | Tubing and sampling accessories in specimen handling pathways |
| Implant or long-term internal contact | Long-term | Outside the range of disposable clinic consumables |
Those bands drive the size of the evaluation, not a fixed number of tests. The weight-of-evidence approach is now the subject of its own literature: a 2024 paper in Regulatory Toxicology and Pharmacology described a weight-of-evidence framework for biocompatibility evaluations, arguing that assembling and grading existing data is central to a defensible file rather than an optional shortcut.
Which Parts of the Series Do the Endpoints?
Once the evaluation plan is set, individual parts of the ISO 10993 series describe endpoints. Commonly referenced ones include part 5 for in vitro cytotoxicity, part 10 for skin sensitisation, part 23 for irritation testing and part 12 for sample preparation and reference materials.
It is worth reading how much room for interpretation sits inside those endpoints. A 2023 paper in Frontiers in Medical Technology argued that the specifications of ISO 10993-5 are not explicit enough on their own to produce comparable results between laboratories. A 2025 study in Toxicology In Vitro described combining three alternative in vitro methods to detect skin sensitisation hazards in medical device materials. The endpoints are structured, and they still rely on professional judgement.
Another strand of the literature looks at where the classic assumptions came from. A 2026 article in ALTEX examined material-mediated pyrogens in medical devices and questioned how much of the historical concern translates into reality for modern materials. That kind of challenge is normal in a framework designed to be revised as evidence accumulates.
| Claim on a specification sheet | What should sit behind it | Question worth asking |
|---|---|---|
| "Biocompatible material" | A completed evaluation plan and endpoint selection | Which framework part was applied, and for which contact category? |
| "Tested to ISO 10993" | Named parts and the laboratory that ran them | Which parts, on what samples, and when? |
| "Skin-friendly adhesive" | Sensitisation and irritation assessment | Was testing done on the finished product or on raw material? |
| "Latex-free" | Material declaration, not a biological endpoint | Is the claim about material composition or about allergy risk? |
| "Medical grade" | A supplier's internal or industry convention | Who defines the term for this product, and against which specification? |
| "Certificate of analysis" | Batch-level conformance data for defined tests | Which tests does the certificate actually cover? |
Reading those two columns together is the difference between accepting a claim and verifying it. The terms are not deceptive by design; they are simply looser than the underlying activity.
Where Do Glove Specifications and Biocompatibility Meet?
Gloves sit at an intersection that confuses buyers most often. ASTM D6319 covers nitrile examination gloves, ASTM D3578 covers rubber examination gloves and ASTM D5250 covers vinyl examination gloves — specifications for dimensions, physical properties, powder and sampling. They are not biocompatibility standards.
Biological questions arrive from a different direction: extractable proteins in natural rubber products, residues from manufacturing, and sensitisation risk. Clinical protection questions add another layer again, which is where permeation and penetration tests such as ASTM D6978 for chemotherapy drugs, ASTM F739 for chemical permeation and ASTM F1670 and F1671 for blood and pathogen penetration come in.
For a clinic converting from latex to nitrile, the file that supports the decision typically contains three types of document: the glove specification the product is manufactured to, the biological evaluation summary for the material, and the lot-level quality evidence the supplier maintains. Wholesale case documentation for the 6 mil black nitrile glove line, for example, is issued per lot rather than per catalogue page, because that is what an audit asks for.
What Should a Buyer Ask, and What Should a Supplier Volunteer?
Suppliers who understand the framework volunteer three things without being asked: the applicable standard edition, the contact category assumed, and the change-notification policy. Buyers who understand it ask four questions that a purely commercial conversation would skip.
- Finished device or material sample? Evidence gathered on a raw material does not automatically transfer to a finished device that has been cut, coated or sterilised.
- Which sterilisation route? Where a product is sterilised, the process can affect residues and material behaviour, so the evaluation should name the process.
- What triggers re-evaluation? Material substitution, supplier change, process change and site change are the usual triggers. Ask which of them the supplier notifies customers about.
- Is the intended use documented in the labelling? A single-use statement, a storage condition or a use limitation in the instructions becomes part of the safety case. If it is missing from what the clinic receives, the assumption is not visible to the people who need it.
Infection prevention guidance reinforces the point from the clinical side. Public Health Ontario's IPAC core elements checklist and the reprocessing checklist both assume that the products arriving in the clinic are suitable for their stated purpose, with single-use items used once and stored as labelled. That assumption is only safe when the supply chain documents it.
CliniEco Medical keeps its own establishment information visible for the same reason: the company is a licensed medical device establishment (MDEL #35334), and the consumables it ships are supplied with the labelling expected for the device classes it handles. Buyers consolidating several product lines can route case quantities through the wholesale desk, and a wholesale account lets a practice evaluate handling and fit before committing to case volumes.
The framework will never be a page a clinic reads for pleasure. But a buyer who can ask which part of the series was applied, on what samples, and what triggers a re-evaluation will get a different quality of answer than one asking only for a price. That difference is what the standard was written to create.
References and standards cited
- ISO 10993-1:2018 Biological evaluation of medical devices, Part 1: Evaluation and testing within a risk management process (link checked 20 September 2026)
- ISO 10993-5:2009 Biological evaluation of medical devices, Part 5: Tests for in vitro cytotoxicity (link checked 20 September 2026)
- ASTM D6319 Standard Specification for Nitrile Examination Gloves for Medical Application (link checked 20 September 2026)
- ASTM D3578 Standard Specification for Rubber Examination Gloves (link checked 20 September 2026)
- ASTM D5250 Standard Specification for Poly(vinyl chloride) Gloves for Medical Application (link checked 20 September 2026)
- ASTM D6978 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs (link checked 20 September 2026)
- ASTM F739 Standard Test Method for Permeation of Liquids and Gases through Protective Clothing Materials (link checked 20 September 2026)
- ASTM F1670 Standard Test Method for Resistance of Materials Used in Protective Clothing to Penetration by Synthetic Blood (link checked 20 September 2026)
- ASTM F1671 Standard Test Method for Resistance of Materials Used in Protective Clothing to Penetration by Blood-Borne Pathogens (link checked 20 September 2026)
- ISO 2859-1 Sampling Procedures for Inspection by Attributes (link checked 20 September 2026)
- Health Canada - Medical Devices Regulations (SOR/98-282) (link checked 20 September 2026)
- Public Health Ontario - IPAC Checklist for Dental Practice, Core Elements (link checked 20 September 2026)
- Public Health Ontario - IPAC Checklist for Dental Practice, Reprocessing (link checked 20 September 2026)
- Taring the scales: Weight-of-evidence framework for biocompatibility evaluations. Regul Toxicol Pharmacol. 2024 (link checked 20 September 2026)
- Material-mediated pyrogens in medical devices: Myth or reality? ALTEX. 2026 (link checked 20 September 2026)
- Current Progress on Biological Evaluation for Medical Devices. Zhongguo Yi Liao Qi Xie Za Zhi. 2021 (link checked 20 September 2026)
- Toxic or not toxic? The specifications of the standard ISO 10993-5 are not explicit enough to yield comparable results. Front Med Technol. 2023 (link checked 20 September 2026)
- Detection of skin sensitization hazards in medical device materials. Toxicol In Vitro. 2025 (link checked 20 September 2026)
Related Reading
- What ISO 10993-5 Cytotoxicity Testing Proves About a Device Material
- ASTM D3578: Type I and Type II Latex Exam Gloves
- ASTM D5250: Dusting Powder, Ageing and PVC Glove Limits
- Glove Contact Dermatitis: Type I Allergy vs Type IV Irritation
- AQL Explained: Medical Glove Quality Standards for Buyers
- Nitrile exam gloves, 4 mil, 100-pack
- Nitrile exam gloves, 6 mil heavy duty black, 100-pack
- Hypoallergenic paper medical tape, 1 inch
- wholesale account
- Wholesale and bulk ordering desk
Frequently Asked Questions
What is ISO 10993-1 in plain terms?
It is the part of the ISO 10993 series that sets the framework for biological evaluation of a medical device: how to plan the evaluation, which categories of body contact and exposure time apply, and how existing data and testing are weighed together inside a risk management process.
Does every piece of clinic supply need its own testing?
No. The framework is staged. Manufacturers first gather existing data, material history and clinical experience; laboratory testing is then used to fill specific gaps. That is why a supplier may cite a material supplier's data package alongside its own tests rather than a full battery for every component.
What does "surface device" mean in this context?
It describes a device that contacts intact skin, mucosal membranes or compromised skin rather than entering the body. Examination gloves, medical tape and disposable gowns are usually treated as surface devices, which is one reason their evidence sets look different from an implant's.
How does contact duration change requirements?
Duration is grouped into limited, prolonged and long-term exposure. A glove worn for a few minutes during a dressing change and a catheter secured for weeks sit in different buckets, so the same material can support different evidence depending on how long it stays in contact.
Do nitrile glove standards cover biocompatibility?
They cover different things. ASTM D6319 sets dimensions, physical properties and sampling for nitrile examination gloves, while the biocompatibility thinking sits in the ISO 10993 framework. A glove can meet a glove specification and still need biological data in its technical file.
What evidence can a clinic ask for?
Ask which framework part applied, which endpoints were considered, whether testing was done on the finished device or on a material sample, who ran it, and how the supplier handles a change of material or manufacturing site. That last question is the one that keeps a file current.
Why is material change control important to buyers?
Because evidence attaches to a specific material and process. A supplier that switches resin, coating or sterilisation method without re-evaluating changes the basis of the claim. Buyers who ask about change notification get a warning before the product in their store room differs from the one that was evaluated.
Where does labelling fit in?
Instructions for use tell staff how a device is intended to be used, including single-use status and storage. If a biocompatibility assumption depends on a use limitation, that limitation has to appear in the labelling a clinic actually receives, not only in a technical file.
Last updated: September 2026. CliniEco Medical is a licensed medical device establishment (MDEL #35334).
0 comments